ABVC BioPharma, Inc. (ABVC)
NASDAQ: ABVC · Real-Time Price · USD
1.340
-0.070 (-4.96%)
Mar 6, 2026, 3:36 PM EST - Market open
ABVC BioPharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | - | 0.51 | 0.15 | 0.97 | 0.36 | Upgrade
|
| Revenue Growth (YoY) | - | 234.31% | -84.28% | 172.57% | -26.34% | Upgrade
|
| Cost of Revenue | - | 0 | 0.3 | 0.29 | 0.01 | Upgrade
|
| Gross Profit | - | 0.51 | -0.15 | 0.68 | 0.35 | Upgrade
|
| Selling, General & Admin | 2.89 | 2.26 | 5.37 | 6.07 | 5.75 | Upgrade
|
| Research & Development | 0.12 | 0.18 | 1.06 | 2.69 | 1 | Upgrade
|
| Operating Expenses | 7.15 | 5.21 | 6.62 | 15.8 | 12.06 | Upgrade
|
| Operating Income | -7.15 | -4.71 | -6.77 | -15.11 | -11.71 | Upgrade
|
| Interest Expense | -0.42 | -0.83 | -1.31 | -0.29 | -0.23 | Upgrade
|
| Interest & Investment Income | 0.17 | 0.09 | 0.19 | 0.19 | 0.04 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.08 | -0.03 | 0.02 | -0.26 | 0.43 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.12 | 0.18 | 0.07 | 0.08 | 0.16 | Upgrade
|
| EBT Excluding Unusual Items | -7.36 | -5.29 | -7.8 | -15.4 | -11.3 | Upgrade
|
| Gain (Loss) on Sale of Investments | -1 | -0.34 | -0.22 | -0.01 | -0.27 | Upgrade
|
| Asset Writedown | - | - | - | -0.11 | - | Upgrade
|
| Other Unusual Items | - | 0.26 | - | - | 0.36 | Upgrade
|
| Pretax Income | -8.35 | -5.37 | -8.02 | -15.51 | -11.21 | Upgrade
|
| Income Tax Expense | 0.02 | -0.11 | 0.26 | 0.8 | 0.83 | Upgrade
|
| Earnings From Continuing Operations | -8.38 | -5.26 | -8.28 | -16.31 | -12.04 | Upgrade
|
| Minority Interest in Earnings | 0.47 | 0.36 | 0.49 | -0.11 | -0.8 | Upgrade
|
| Net Income | -7.91 | -4.9 | -7.79 | -16.42 | -12.84 | Upgrade
|
| Net Income to Common | -7.91 | -4.9 | -7.79 | -16.42 | -12.84 | Upgrade
|
| Shares Outstanding (Basic) | 20 | 12 | 4 | 3 | 3 | Upgrade
|
| Shares Outstanding (Diluted) | 20 | 12 | 4 | 3 | 3 | Upgrade
|
| Shares Change (YoY) | 72.25% | 169.26% | 36.92% | 26.39% | 27.07% | Upgrade
|
| EPS (Basic) | -0.39 | -0.42 | -1.80 | -5.19 | -5.12 | Upgrade
|
| EPS (Diluted) | -0.39 | -0.42 | -1.80 | -5.19 | -5.12 | Upgrade
|
| Free Cash Flow | -2.99 | -1.81 | -4.21 | -7.52 | -7.62 | Upgrade
|
| Free Cash Flow Per Share | -0.15 | -0.15 | -0.97 | -2.37 | -3.04 | Upgrade
|
| Gross Margin | - | 99.85% | -98.15% | 70.47% | 98.57% | Upgrade
|
| Operating Margin | - | -923.34% | -4439.24% | -1558.54% | -3290.07% | Upgrade
|
| Profit Margin | - | -962.12% | -5109.26% | -1693.50% | -3608.47% | Upgrade
|
| Free Cash Flow Margin | - | -355.02% | -2760.64% | -775.23% | -2140.33% | Upgrade
|
| EBITDA | -7.13 | -4.67 | -6.74 | -15.09 | -11.69 | Upgrade
|
| D&A For EBITDA | 0.03 | 0.03 | 0.03 | 0.02 | 0.01 | Upgrade
|
| EBIT | -7.15 | -4.71 | -6.77 | -15.11 | -11.71 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.